Home
Clinical Trials
Atorvastatin Effectiveness an...

Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting

Last Updated: 2021-02-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5115 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-22

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR

NCT01761656

Stable Angina Unstable Angina Acute Non-ST-segment Elevation Myocardial Infarction

UNKNOWN PHASE2

Atorvastatin in Pulmonary Hypertension

NCT00615823

Hypertension, Pulmonary

COMPLETED PHASE2

Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome

NCT00728988

Acute Coronary Syndrome

COMPLETED PHASE4

The Effects of Atorvastatin in Patients With Atherosclerosis

NCT00115817

Atherosclerosis

COMPLETED PHASE3

Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention

NCT00610870

Angioplasty, Transluminal, Percutaneous Coronary

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease, Hypercholesterolemia, Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atorvastatin dose titration (single-arm)

Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator

No intervention

Intervention Type OTHER

Because this is a non-interventional study, there is no intervention here.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Because this is a non-interventional study, there is no intervention here.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged ≥18 years;
* Cardiology patients who has been prescribed atorvastatin by physician's clinical judgment under normal clinical care. These patients will include those with established coronary heart disease, or having multiple risk factors and at risk for cardiovascular disease, or primary hypercholesterolemia.
* Baseline laboratory reports prior to starting atorvastatin therapy can be tracked , including lipid measurement, liver function, and Creatine Kinase (CK) value. The date of baseline reports should be within 1 month before taking atorvastatin or within 24h after starting atorvastatin therapy.
* Evidence of a personally or his/her legally acceptable representative signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study and accept follow-up visit.

Exclusion Criteria

* Patients who have regularly taken atorvastatin therapy more than 4 weeks before enrollment
* Concomitant any other lipid-lower medication at baseline, or during the study conduction on physician clinical judgement

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.